
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is facing financial challenges, as evidenced by their recent modest $1M financing and the potential for future dilution as they continue to fund clinical development and other operational needs. However, their strategic value remains strong, particularly with the exclusive Emory license for Gedeptin and the ongoing global transmission concerns for mpox. Although the potential for near-term share price support is low, the company is aiming for a pivotal year in 2026 with multiple clinical readouts and regulatory de-risking, which could position them for success in the future.
Bears say
Geovax Labs is facing challenges with a secondary pipeline that is unlikely to provide significant value in the near term. The company's efforts to develop potential vaccines for infectious diseases and solid tumor cancer are still far from generating substantial revenue. Furthermore, recent reverse stock split and potential future capital raises may bring heightened dilution risk and investor sensitivity. Even though the company's most advanced program, GEO-MVA, has received positive feedback, commercialization and potential revenue generation are still years away.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares